First-line treatment of indolent lymphoma: axing CHOP?
Mené sur 274 patients atteints d'un lymphome indolent ou à cellules du manteau, cette étude multicentrique allemande compare l'efficacité, du point de vue de la survie sans progression, d'un traitement de première ligne combinant bendamustine et rituximab par rapport à une combinaison R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine et prednisone)
About 30 000 new cases of indolent non-Hodgkin's lymphoma occurred in the USA in 2012. Despite advances in our understanding of the molecular and genetic bases of these diseases, and perhaps because of their long natural history, little improvement was made in the management and survival of patients in the past 3—4 decades, until the introduction of rituximab. Although no randomised trials have been done to support the use of multidrug chemoimmunotherapy with anthracyclines in low-intensity ch ...
The Lancet , commentaire, 2012